Table 17 C

A Chronic Feeding Study
of Glyphosate (ROUNDUP® Technical) in Mice
Pathology Report

Summary-Incidence of Neoplastic Findings - Male Mice
Total - Male Mice

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	MALE			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** TOP OF LIST **				
PITUITARY GLAND (PG) ..... NUMBER EXAMINED:	32	18	32	32
BRAIN (BN) ..... NUMBER EXAMINED:	49	50	50	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS, METASTATIC	0 0%	0 0%	1 2%	0 0%
CERVICAL SC (SC0) ..... NUMBER EXAMINED:	49	48	50	50
THORACOLUMBAR SC (SC1) ..... NUMBER EXAMINED:	10	8	10	23
HEART (HT) ..... NUMBER EXAMINED:	47	49	49	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0 0%	1 2%	2 4%	1 2%
AORTA (AO) ..... NUMBER EXAMINED:	46	50	50	47
TRACHEA (TR) ..... NUMBER EXAMINED:	48	50	50	49
ESOPHAGUS (ES) ..... NUMBER EXAMINED:	48	50	50	48
LUNGS (LU) ..... NUMBER EXAMINED:	48	50	50	50
--B- BRONCHIOLAR-ALVEOLAR ADENOMA	5 10%	9 18%	9 18%	9 18%
--M- BRONCHIOLAR-ALVEOLAR ADENOCARCINOMA	4 8%	3 6%	2 4%	1 2%
--S- GRANULOSA CELL TUMOR	0 0%	0 0%	0 0%	0 0%
--S- LEIOMYOSARCOMA	0 0%	0 0%	0 0%	0 0%
--S- LIPOSARCOMA	0 0%	0 0%	0 0%	0 0%
--S- COMPOSITE LYMPHOSARCOMA	0 0%	0 0%	0 0%	0 0%

** CONTINUED ON NEXT PAGE **

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
LUNGS (LU) ..... NUMBER EXAMINED:	48	50	50	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	4	3	1
	2%	8%	6%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	1	0	0
	0%	2%	0%	0%
LIVER (LI) ..... NUMBER EXAMINED:	49	50	50	50
--M- HEPATOCELLULAR ADENOCARCINOMA	5	6	6	4
	10%	12%	12%	8%
--B- HEPATOCELLULAR ADENOMA	0	0	1	0
	0%	0%	2%	0%
--M- HEPATOCELLULAR CARCINOMA	0	0	0	2
	0%	0%	0%	4%
--M- HEMANGIOENDOTHELIOMA	0	0	0	0
	0%	0%	0%	0%
--S- HISTIOCYTIC SARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	0	0	0
	0%	0%	0%	0%
--S- LIPOSARCOMA	0	0	1	1
	0%	0%	2%	2%
--S- HEMANGIOENDOTHELIOMA	0	0	0	0
	0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%

* CONTINUED ON NEXT PAGE **

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED-			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
LIVER (LI) ..... NUMBER EXAMINED:	49	50	50	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1 2%	4 8%	2 4%	2 4%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0 0%	0 0%	0 0%	0 0%
GALLBLADDER (GB) ..... NUMBER EXAMINED:	45	32	36	41
MESENTERIC LN (LNO) ..... NUMBER EXAMINED:	48	50	46	49
--M- HISTIOCYTIC SARCOMA	0 0%	1 2%	0 0%	0 0%
--S- LEIOMYOSARCOMA	0 0%	0 0%	0 0%	0 0%
--S- GRANULOCYTIC LEUKEMIA	0 0%	0 0%	0 0%	0 0%
--S- ENDOMETRIAL ADENOCARCINOMA	0 0%	0 0%	0 0%	0 0%
--M- COMPOSITE LYMPHOSARCOMA	1 2%	0 0%	1 2%	0 0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1 2%	2 4%	1 2%	0 0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0 0%	0 0%	1 2%	2 4%
--S- COMPOSITE LYMPHOSARCOMA	0 0%	0 0%	0 0%	0 0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA	0 0%	1 2%	0 0%	0 0%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
MESENTERIC LN (LN0) ..... NUMBER EXAMINED:	48	50	46	49
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- HEMANGIOENDOTHELIOMA	0	0	0	0
	0%	0%	0%	0%
MEDIASTINAL LN (LN1) ..... NUMBER EXAMINED:	45	49	41	49
--S- HISTIOCYTIC SARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	0	0	0
	0%	0%	0%	0%
--S- LIPOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	0	1	0
	2%	0%	2%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	2	1	2
	2%	4%	2%	4%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	2	0
	0%	0%	5%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
SALIVARY GLANDS (SG) ..... NUMBER EXAMINED:	49	50	49	50
--S- LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%

** CONTINUED ON NEXT PAGE **

OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
SALIVARY GLANDS (SG) ..... NUMBER EXAMINED:	49	50	49	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	1	0
	2%	0%	2%	0%
THYMUS (TM) ..... NUMBER EXAMINED:	2	0	1	1
PLEEN (SP) ..... NUMBER EXAMINED:	48	49	50	49
--M- HEMANGIOENDOTHELIOMA	0	0	1	0
	0%	0%	2%	0%
--B- HEMANGIOMA	0	0	0	0
	0%	0%	0%	0%
--S- HISTIOCYTIC SARCOMA	0	1	0	0
	0%	2%	0%	.0%
--M- GRANULOCYTIC LEUKEMIA	0	0	0	0
	0%	0%	0%	0%
--S- ENDOMETRIAL ADENOCARCINOMA	0	0	0	0
	0%	0%	0%	0%
--S- HEMANGIOENDOTHELIOMA	0	0	0	0
	0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	0	1	0
	2%	0%	2%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	2	2	0
	2%	4%	4%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	2	0	1
	0%	4%	0%	2%
--M- COMPOSITE LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%

** CONTINUED ON NEXT PAGE **

OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
SPLEEN (SP) ..... NUMBER EXAMINED:	48	49	50	49
--M- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
STOMACH (ST) ..... NUMBER EXAMINED:	49	47	48	49
--M- LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--M- GASTRIC ADENOCARCINOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	0	0
	2%	0%	0%	0%
DUODENUM (DU) ..... NUMBER EXAMINED:	46	43	44	48
--S- COMPOSITE LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
PANCREAS (PA) ..... NUMBER EXAMINED:	48	48	49	50
--S- HISTIOCYTIC SARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	0	0	0
	0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	1	0
	0%	0%	2%	0%
JEJUNUM (JE) ..... NUMBER EXAMINED:	46	41	41	47
--S- COMPOSITE LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%

TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	--------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
ILEUM (IL) ..... NUMBER EXAMINED:	47	41	40	48
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	0	0
	2%	0%	0%	0%
CECUM (CE) ..... NUMBER EXAMINED:	45	43	47	47
--S- COMPOSITE LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	0	0
	2%	0%	0%	0%
COLON (CO) ..... NUMBER EXAMINED:	46	47	47	48
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
KIDNEYS (KD) ..... NUMBER EXAMINED:	49	49	50	50
--B- RENAL TUBULE ADENOMA	0	0	1	3
	0%	0%	2%	6%
--S- B/ HISTIOCYTIC SARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- B/ LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- B/ GRANULOCYTIC LEUKEMIA	0	0	0	0
	0%	0%	0%	0%
--S- B/ COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%

** CONTINUED ON NEXT PAGE **

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

RGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
.. FROM PREVIOUS PAGE **				
IDNEYS (KD) ..... NUMBER EXAMINED:	49	49	50	50
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1 2%	3 6%	2 4%	2 4%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA	0 0%	0 0%	0 0%	0 0%
TESTES (TE) ..... NUMBER EXAMINED:	49	48	50	50
--B- U/ INTERSTITIAL CELL TUMOR	1 2%	0 0%	2 4%	0 0%
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0 0%	1 2%	0 0%	0 0%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0 0%	0 0%	1 2%	0 0%
EPIDIDYMIDES (EP) ..... NUMBER EXAMINED:	49	48	50	50
--M- U/ LEIOMYOSARCOMA	0 0%	1 2%	0 0%	1 2%
PROSTATE (PR) ..... NUMBER EXAMINED:	49	47	50	49
URINARY BLADDER (UB) ..... NUMBER EXAMINED:	48	46	47	47
--S-HISTIOCYTICSARCOMA	0 0%	1 2%	0 0%	0 0%
--S- GRANULOCYTIC LEUKEMIA	0 0%	0 0%	0 0%	0 0%
--S- COMPOSITE LYMPHOSARCOMA	0 0%	0 0%	0 0%	0 0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1 2%	1 2%	0 0%	0 0%

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION — NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
OVARIES (OV) ..... NUMBER EXAMINED:	0	0	0	0
--B- U/ LUTEOMA	0	0	0	0
	0%	0%	0%	0%
--M- B/ MALIGNANT TERATOMA	0	0	0	0
	0%	0%	0%	0%
--M- B/ GRANULOSA CELL TUMOR	0	0	0	0
	0%	0%	0%	0%
--S- B/ LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--I- B/ ENDOMETRIAL ADENOCARCINOMA	0	0	0	0
	0%	0%	0%	0%
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
--S- B/ COMPOSITE LYMPHOSARCOMA	0	0	0	0
	0%	0%	0%	0%
UTERUS (UT) ..... NUMBER EXAMINED:	0	0	0	0
--B- LIEOMYOMA	0	0	0	0
	0%	0%	0%	0%
--M- LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--M- ENDOMETRIAL STROMAL CELL SARCOMA	0	0	0	0
	0%	0%	0%	0%
--B- HEMANGIOMA	0	0	0	0
	0%	0%	0%	0%

** CONTINUED ON NEXT PAGE **

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	--------MALE--------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
UTERUS (UT) ..... NUMBER EXAMINED:	0	0	0	0
--M- ENDOMETRIAL ADENOCARCINOMA	0	0	0	0
	0%	0%	0%	0%
--M- HEMANGIOENDOTHELIOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
ROID GLAND (TH) ..... NUMBER EXAMINED:	40	40	50	48
--B- FOLLICULAR ADENOMA	0	0	0	0
	0%	0%	0%	0%
PARATHYROID GLS. (PT) ..... NUMBER EXAMINED:	17	23	22	15
ENAL GLANDS (AD) ..... NUMBER EXAMINED:	48	49	50	48
--B- U/ CORTICAL ADENOMA	1	2	0	1
	2%	4%	0%	2%
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	1	0	0
	0%	2%	0%	0%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	1	0
	0%	0%	2%	0%
N/SUBQ/EARS (SK) ..... NUMBER EXAMINED:	49	48	48	47
--M- FIBROSARCOMA	0	0	1	0
	0%	0%	2%	0%
--M- LIPOSARCOMA	0	0	0	1
	0%	0%	0%	2%
--M- RHABDOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%

CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	-------MALE-------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
SKIN/SUBQ/EARS (SK) ..... NUMBER EXAMINED:	49	48	48	47
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	1	0
	0%	0%	2%	0%
MAMMARY (MG) ..... NUMBER EXAMINED:	1	0	2	2
--M- DUCTAL ADENOCARCINOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
MUSCLE (SM) ..... NUMBER EXAMINED:	49	50	50	49
--S- LIPOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
NERVE (NE) ..... NUMBER EXAMINED:	39	49	48	42
EYES (EY) ..... NUMBER EXAMINED:	41	41	44	44
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	1	0
	2%	0%	2%	0%
HARDERIAN GLAND (HG) ..... NUMBER EXAMINED:	47	48	45	48
--B- ADENOMA	1	0	0	0
	2%	0%	0%	0%
--M- LIPOSARCOMA	0	0	1	0
	0%	0%	2%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
BONE (BO) ..... NUMBER EXAMINED:	43	45	45	48

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

BLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

GAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	-------MALE-------			
	GROUP:	-1-	-2-	-3-	-4-
	NUMBER:	50	50	50	50
FROM PREVIOUS PAGE **					
NE MARROW (BM)	NUMBER EXAMINED:	48	45	47	49
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		1	2	1	1
		2%	4%	2%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA		0	0	0	0
		0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA		0	0	0	0
		0%	0%	0%	0%
MINAL VESICLES (SV)	NUMBER EXAMINED:	14	8	13	13
IL (TA)	NUMBER EXAMINED:	14	9	6	19
AGULAT. GLAND (CG)	NUMBER EXAMINED:	1	0	0	0
DOMEN (AB)	NUMBER EXAMINED:	0	0	0	0
ALL INTESTINES (SI)	NUMBER EXAMINED:	0	0	0	0
EPUTIAL GLAND (PP)	NUMBER EXAMINED:	2	2	3	0
SENTERY (ME)	NUMBER EXAMINED:	0	2	0	0
--B- HEMANGIOMA		0	1	0	0
		0%	50%	0%	0%
--S- TERATOMA		0	0	0	0
		0%	0%	0%	0%
NERAL COMMENTS (GC)	NUMBER EXAMINED:	0	0	0	0

CONF.
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0167

BLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	--------MALE--------			
	GROUP:	-1-	-2-	-3-	-4-
	NUMBER:	50	50	50	50
GINA (VA)	NUMBER EXAMINED:	0	0	0	0
--M- LEIOMYOSARCOMA		0	0	0	0
		0%	0%	0%	0%
MPH NODE (LN)	NUMBER EXAMINED:	0	3	2	2
--S- HISTIOCYTIC SARCOMA		0	1	0	0
		0%	33%	0%	0%
--S- GRANULOCYTIC LEUKEMIA		0	0	0	0
		0%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA		0	0	1	0
		0%	0%	50%	0%
--M- COMPOSITE LYMPHOSARCOMA		0	0	0	0
		0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	1	1	0
		0%	33%	50%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	0	1
		0%	0%	0%	50%
PENIS (PE)	NUMBER EXAMINED:	1	5	7	0
OMINAL CAVITY (AC)	NUMBER EXAMINED:	0	0	0	0
'ITY (CA)	NUMBER EXAMINED:	0	0	0	0
NAL CORD (SC)	NUMBER EXAMINED:	0	0	0	0
GASTROINTESTINES (GI)	NUMBER EXAMINED:	0	0	0	0
TERS (UR)	NUMBER EXAMINED:	0	0	1	0
ADIPOSE TISSUE (AT)	NUMBER EXAMINED:	0	0	1	0
--M- LIPOSARCOMA		0	0	1	0
		0%	0%	100%	0%

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0168

TABLE INCLUDES: SEX=M;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	-------MALE-------			
	GROUP:	-1-	-2-	-3-	-4-
	NUMBER:	50	50	50	50
HEAD SECTIONS (NT)	NUMBER EXAMINED:	10	8	10	10
--B- DENTINOMA		0	0	0	0
		0%	0%	0%	0%
JUNCTION (JU)	NUMBER EXAMINED:	0	0	0	0
CORRELATE #1 (G1)	NUMBER EXAMINED:	0	0	0	0
CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0
--M- LEIOMYOSARCOMA		0	0	0	0
		0%	0%	0%	0%
MUSCLE OTHER (MU)	NUMBER EXAMINED:	0	0	0	0
--S- COMPOSITE LYMPHOSARCOMA		0	0	0	0
		0%	0%	0%	0%
CORRELATE #2 (G2)	NUMBER EXAMINED:	0	0	0	0

** END OF LIST **

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

Table 18 C

A Chronic Feeding Study
of Glyphosate (ROUNDUP® Technical) in Mice
Pathology Report

Summary-Incidence of Neoplastic Findings - Female Mice
Total - Female Mice

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** TOP OF LIST **				
PITUITARY GLAND (PG) ..... NUMBER EXAMINED:	32	21	44	37
BRAIN (BN) ..... NUMBER EXAMINED:	50	49	50	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS, METASTATIC	0 0%	0 0%	1 2%	0 0%
CERVICAL SC (SC0) ..... NUMBER EXAMINED:	48	49	49	49
THORACOLUMBAR SC (SC1) ..... NUMBER EXAMINED:	10	9	8	12
HEART (HT) ..... NUMBER EXAMINED:	50	50	50	49
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0 0%	0 0%	2 4%	0 0%
AORTA (AO) ..... NUMBER EXAMINED:	47	49	49	47
TRACHEA (TR) ..... NUMBER EXAMINED:	47	50	50	48
ESOPHAGUS (ES) ..... NUMBER EXAMINED:	48	50	50	50
LUNGS (LU) ..... NUMBER EXAMINED:	49	50	49	50
--B- BRONCHIOLAR-ALVEOLAR ADENOMA	10 20%	9 18%	10 20%	1 2%
--M- BRONCHIOLAR-ALVEOLAR ADENOCARCINOMA	1 2%	3 6%	4 8%	4 8%
--S- GRANULOSA CELL TUMOR	0 0%	1 2%	0 0%	0 0%
--S- LEIOMYOSARCOMA	0 0%	1 2%	0 0%	0 0%
--S- LIPOSARCOMA	1 2%	0 0%	0 0%	0 0%
--S- COMPOSITE LYMPHOSARCOMA	1 2%	0 0%	0 0%	1 2%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0321

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
LUNGS (LU) ..... NUMBER EXAMINED:	49	50	49	50
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	2	5	1
	2%	4%	10%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
LIVER (LI) ..... NUMBER EXAMINED:	49	50	49	49
--M- HEPATOCELLULAR ADENOCARCINOMA	1	2	1	0
	2%	4%	2%	0%
--B- HEPATOCELLULAR ADENOMA	0	1	0	0
	0%	2%	0%	0%
--M- HEPATOCELLULAR CARCINOMA	0	0	0	0
	0%	0%	0%	0%
--M- HEMANGIOENDOTHELIOMA	0	0	1	0
	0%	0%	2%	0%
--S- HISTIOCYTIC SARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LEIOMYOSARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	3	0	0
	0%	6%	0%	0%
--S- LIPOSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- HEMANGIOENDOTHELIOMA	0	0	2	0
	0%	0%	4%	0%
--S- COMPOSITE LYMPHOSARCOMA	2	1	0	4
	4%	2%	0%	8%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
LIVER (LI) ..... NUMBER EXAMINED:	49	50	49	49
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	4	4	1
	2%	8%	8%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	2
	0%	0%	0%	4%
GALLBLADDER (GB) ..... NUMBER EXAMINED:	36	42	41	44
MESENTERIC LN (LNO) ..... NUMBER EXAMINED:	49	49	48	48
--M- HISTIOCYTIC SARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LEIOMYOSARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	1	0	0
	0%	2%	0%	0%
--S- ENDOMETRIAL ADENOCARCINOMA	1	0	0	0
	2%	0%	0%	0%
--M- COMPOSITE LYMPHOSARCOMA	2	0	0	1
	4%	0%	0%	2%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	3	1	1
	0%	6%	2%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	1	3	0
	2%	2%	6%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	1	1	3
	2%	2%	2%	6%
--M- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	2
	0%	0%	0%	4%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0303

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
MESENTERIC LN (LN0) ..... NUMBER EXAMINED:	49	49	48	48
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
--S- HEMANGIOENDOTHELIOMA	0	0	0	1
	0%	0%	0%	2%
MEDIASTINAL LN (LN1) ..... NUMBER EXAMINED:	42	48	39	47
--S- HISTIOCYTIC SARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- LEIOMYOSARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	1	0	0
	0%	2%	0%	0%
--S- LIPOSARCOMA	1	0	0	0
	2%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	1	0	2
	2%	2%	0%	4%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	1	3	0
	0%	2%	8%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	1	2	0
	2%	2%	5%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
SALIVARY GLANDS (SG) ..... NUMBER EXAMINED:	50	50	50	47
--S- LEIOMYOSARCOMA	0	0	1	0
	0%	0%	2%	0%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
SALIVARY GLANDS (SG) ..... NUMBER EXAMINED:	50	50	50	47
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	1	1	0
	0%	2%	2%	0%
THYMUS (TM) ..... NUMBER EXAMINED:	2	2	2	1
SPLEEN (SP) ..... NUMBER EXAMINED:	50	48	49	49
--M- HEMANGIOENDOTHELIOMA	1	0	2	1
	2%	0%	4%	2%
--B- HEMANGIOMA	0	0	1	0
	0%	0%	2%	0%
--S- HISTIOCYTIC SARCOMA	0	0	0	0
	0%	0%	0%	0%
--M- GRANULOCYTIC LEUKEMIA	0	3	0	0
	0%	6%	0%	0%
--S- ENDOMETRIAL ADENOCARCINOMA	1	0	0	0
	2%	0%	0%	0%
--S- HEMANGIOENDOTHELIOMA	0	0	0	1
	0%	0%	0%	2%
--S- COMPOSITE LYMPHOSARCOMA	2	0	0	1
	4%	0%	0%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	2	2	0
	2%	4%	4%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	2	0
	0%	0%	4%	0%
--M- COMPOSITE LYMPHOSARCOMA	1	1	1	5
	2%	2%	2%	10%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
SPLEEN (SP) ..... NUMBER EXAMINED:	50	48	49	49
--M- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
STOMACH (ST) ..... NUMBER EXAMINED:	48	49	50	50
--M- LEIOMYOSARCOMA	0	0	1	0
	0%	0%	2%	0%
--M- GASTRIC ADENOCARCINOMA	0	0	1	0
	0%	0%	2%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
DUODENUM (DU) ..... NUMBER EXAMINED:	43	47	48	49
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%
PANCREAS (PA) ..... NUMBER EXAMINED:	47	49	49	50
--S- HISTIOCYTIC SARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	1	0	0
	0%	2%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	2	1	0	1
	4%	2%	0%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	1	1	0
	2%	2%	2%	0%
JEJUNUM (JE) ..... NUMBER EXAMINED:	42	42	44	48
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
ILEUM (IL) ..... NUMBER EXAMINED:	43	43	43	49
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
CECUM (CE) ..... NUMBER EXAMINED:	44	45	49	50
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
COLON (CO) ..... NUMBER EXAMINED:	49	44	48	50
--S- COMPOSITE LYMPHOSARCOMA	1	0	0	0
	2%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	0	0
	2%	0%	0%	0%
KIDNEYS (KD) ..... NUMBER EXAMINED:	50	50	50	50
--B- RENAL TUBULE ADENOMA	0	0	0	0
	0%	0%	0%	0%
--S- B/ HISTIOCYTIC SARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- B/ LEIOMYOSARCOMA	0	1	0	0
	0%	2%	0%	0%
--S- B/ GRANULOCYTIC LEUKEMIA	0	1	0	0
	0%	2%	0%	0%
--S- B/ COMPOSITE LYMPHOSARCOMA	2	1	1	2
	4%	2%	2%	4%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0207

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
KIDNEYS (KD) ..... NUMBER EXAMINED:	50	50	50	50
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	2	3	1
	2%	4%	6%	2%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
TESTES (TE) ..... NUMBER EXAMINED:	0	0	0	0
--B- U/ INTERSTITIAL CELL TUMOR	0	0	0	0
	0%	0%	0%	0%
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	0	0	0
	0%	0%	0%	0%
EPIDIDYMIDES (EP) ..... NUMBER EXAMINED:	0	0	0	0
--M- U/ LEIOMYOSARCOMA	0	0	0	0
	0%	0%	0%	0%
PROSTATE (PR) ..... NUMBER EXAMINED:	0	0	0	0
URINARY BLADDER (UB) ..... NUMBER EXAMINED:	47	43	49	48
--S-HISTIOCYTICSARCOMA	0	0	0	0
	0%	0%	0%	0%
--S- GRANULOCYTIC LEUKEMIA	0	1	0	0
	0%	2%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA	1	1	0	0
	2%	2%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	2	2	0
	2%	5%	4%	0%

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL.
DEATH=ALL ;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED --			
SEX:	------FEMALE------			
GROUP:	-1-	-2-	-3-	-4-
NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **				
OVARIES (OV) ..... NUMBER EXAMINED:	47	47	50	47
--B- U/ LUTEOMA	0	0	1	0
	0%	0%	2%	0%
--M- B/ MALIGNANT TERATOMA	0	1	0	0
	0%	2%	0%	0%
--M- B/ GRANULOSA CELL TUMOR	0	1	0	0
	0%	2%	0%	0%
--S- B/ LEIOMYOSARCOMA	0	1	0	0
	0%	2%	0%	0%
--I- B/ ENDOMETRIAL ADENOCARCINOMA	1	0	0	0
	2%	0%	0%	0%
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	0	1	0	0
	0%	2%	0%	0%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS	1	0	2	0
	2%	0%	4%	0%
--S- B/ COMPOSITE LYMPHOSARCOMA	0	0	0	1
	0%	0%	0%	2%
UTERUS (UT) ..... NUMBER EXAMINED:	49	48	49	50
--B- LIEOMYOMA	2	1	1	1
	4%	2%	2%	2%
--M- LEIOMYOSARCOMA	2	3	2	3
	4%	6%	4%	6%
--M- ENDOMETRIAL STROMAL CELL SARCOMA	0	1	0	0
	0%	2%	0%	0%
--B- HEMANGIOMA	0	1	0	0
	0%	2%	0%	0%

** CONTINUED ON NEXT PAGE **

TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION	NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **					
UTERUS (UT) ..... NUMBER EXAMINED:		49	48	49	50
--M- ENDOMETRIAL ADENOCARCINOMA		2	1	0	0
		4%	2%	0%	0%
--M- HEMANGIOENDOTHELIOMA		0	0	0	1
		0%	0%	0%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	3	1	0
		0%	6%	2%	0%
THYROID GLAND (TH) ..... NUMBER EXAMINED:		43	37	49	48
--B- FOLLICULAR ADENOMA		0	0	1	0
		0%	0%	2%	0%
PARATHYROID GLS. (PT) ..... NUMBER EXAMINED:		11	18	27	15
ADRENAL GLANDS (AD) ..... NUMBER EXAMINED:		50	47	49	49
--B- U/ CORTICAL ADENOMA		0	0	0	0
		0%	0%	0%	0%
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	0	0
		0%	0%	0%	0%
--S- B/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	0	0
		0%	0%	0%	0%
SKIN/SUBQ/FARS (SK) ..... NUMBER EXAMINED:		45	45	49	48
--M- FIBROSARCOMA		0	1	1	0
		0%	2%	2%	0%
--M- LIPOSARCOMA		1	0	0	0
		2%	0%	0%	0%
--M- RHABDOMYOSARCOMA		1	0	0	0
		2%	0%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA		0	0	0	0
		0%	0%	0%	0%

** CONTINUED ON NEXT PAGE **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION	NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **					
SKIN/SUBQ/FARS (SK)	NUMBER EXAMINED:	45	45	49	48
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	3	0
		0%	0%	6%	0%
MAMMARY (MG)	NUMBER EXAMINED:	38	36	40	38
--M- DUCTAL ADENOCARCINOMA		2	4	2	1
		5%	11%	5%	3%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	1	0
		0%	0%	3%	0%
MUSCLE (SM)	NUMBER EXAMINED:	50	50	50	49
--S- LIPOSARCOMA		1	0	0	0
		2%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		1	0	1	0
		2%	0%	2%	0%
NERVE (NE)	NUMBER EXAMINED:	41	45	49	47
EYES (EY)	NUMBER EXAMINED:	41	37	41	42
--S- U/ LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	0	0
		0%	0%	0%	0%
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	45	48	49	44
--B- ADENOMA		2	0	1	0
		4%	0%	2%	0%
--M- LIPOSARCOMA		0	0	0	0
		0%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	1	0
		0%	0%	2%	0%
BONE (BO)	NUMBER EXAMINED:	47	48	49	41

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0041

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,R,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-
	NUMBER:	50	50	50	50
** FROM PREVIOUS PAGE **					
BONE MARROW (BM)	NUMBER EXAMINED:	46	49	47	49
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	1	3	1
		0%	2%	6%	2%
--S- LYMPHOBLASTIC LYMPHOSARCOMA		0	0	0	2
		0%	0%	0%	4%
--S- COMPOSITE LYMPHOSARCOMA		0	0	0	1
		0%	0%	0%	2%
SEMINAL VESICLES (SV)	NUMBER EXAMINED:	0	0	0	0
TAIL (TA)	NUMBER EXAMINED:	13	10	10	11
COAGULAT. GLAND (CG)	NUMBER EXAMINED:	0	0	0	0
ABDOMEN (AB)	NUMBER EXAMINED:	0	0	0	0
SMALL INTESTINES (SI)	NUMBER EXAMINED:	0	0	0	0
PREPUTIAL GLAND (PP)	NUMBER EXAMINED:	0	0	1	0
MESENTERY (ME)	NUMBER EXAMINED:	2	1	5	0
--B- HEMANGIOMA		0	0	0	0
		0%	0%	0%	0%
--S- TERATOMA		0	1	0	0
		0%	100%	0%	0%
GENERAL COMMENTS (GC)	NUMBER EXAMINED:	0	0	0	0

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-
	NUMBER:	50	50	50	50
VAGINA (VA)	NUMBER EXAMINED:	1	0	0	0
--M- LEIOMYOSARCOMA		1	0	0	0
		100%	0%	0%	0%
LYMPH NODE (LN)	NUMBER EXAMINED:	5	4	3	1
--S- HISTIOCYTIC SARCOMA		0	0	0	0
		0%	0%	0%	0%
--S- GRANULOCYTIC LEUKEMIA		0	1	0	0
		0%	25%	0%	0%
--S- COMPOSITE LYMPHOSARCOMA		2	1	0	1
		40%	25%	0%	100%
--M- COMPOSITE LYMPHOSARCOMA		1	0	0	0
		20%	0%	0%	0%
--S- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		1	1	0	0
		20%	25%	0%	0%
--M- LYMPHOBLASTIC LYMPHOSARCOMA WITH LEUKEMIC MANIFESTATIONS		0	0	0	0
		0%	0%	0%	0%
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0
ABDOMINAL CAVITY (AC)	NUMBER EXAMINED:	0	0	0	1
CAVITY (CA)	NUMBER EXAMINED:	0	0	1	1
SPINAL CORD (SC)	NUMBER EXAMINED:	0	0	0	0
GASTROINTESTINES (GI)	NUMBER EXAMINED:	0	0	0	0
URETERS (UR)	NUMBER EXAMINED:	0	0	0	0
ADIPOSE TISSUE (AT)	NUMBER EXAMINED:	0	0	0	0
--M- LIPOSARCOMA		0	0	0	0
		0%	0%	0%	0%

OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY

0243

TABLE INCLUDES: SEX=F;GROUP=ALL;SCREEN=ALL;WEEKS=ALL
DEATH=ALL;FIND=M,B,X,I,S;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---			
	SEX:	------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-
	NUMBER:	50	50	50	50
HEAD SECTIONS (NT)	NUMBER EXAMINED:	11	9	8	10
--B- DENTINOMA		1	0	0	0
		9%	0%	0%	0%
JUNCTION (JU)	NUMBER EXAMINED:	0	0	0	0
CORRELATE #1 (G1)	NUMBER EXAMINED:	0	0	0	0
CERVIX (CV)	NUMBER EXAMINED:	0	2	0	1
--M- LEIOMYOSARCOMA		0	2	0	0
		0%	100%	0%	0%
MUSCLE OTHER (MU)	NUMBER EXAMINED:	0	0	0	1
--S- COMPOSITE LYMPHOSARCOMA		0	0	0	1
		0%	0%	0%	100%
CORRELATE #2 (G2)	NUMBER EXAMINED:	0	0	0	0

** END OF LIST **

CONTAINS TRADE SECRET OR
OTHERWISE CONFIDENTIAL
INFORMATION OF
MONSANTO COMPANY